Pharmaceutical Mergers and Their Effect on Access and Efficiency: A Case of Emerging Markets

25 Pages Posted: 24 Apr 2016 Last revised: 26 Apr 2016

See all articles by Vikas Kathuria

Vikas Kathuria

Max Planck Institute for Innovation and Competition

Date Written: April 20, 2016

Abstract

The pharmaceutical M&As in emerging markets may jeopardies cheap access to generics. This may be a motivation for policy makers to use competition law as a tool to deter cross-border M&As. Additionally, M&As in pharmaceutical sector may also give rise to certain efficiencies. However, it is not clear as to how efficiencies will be treated in the peculiar socio-economic context of emerging markets. This paper develops a theoretical framework, which argues that the application of competition law is guided by sector-specific socio-economic realities and institutional realities of the jurisdiction. Thereafter, it employs this framework to analyze both the issues.

Keywords: pharmaceuticals, M&A, access, efficiency, competition law, emerging markets

JEL Classification: K4, K21, L40

Suggested Citation

Kathuria, Vikas, Pharmaceutical Mergers and Their Effect on Access and Efficiency: A Case of Emerging Markets (April 20, 2016). World Competition: Law and Economics Review, 2016 (Forthcoming). Available at SSRN: https://ssrn.com/abstract=2767404

Vikas Kathuria (Contact Author)

Max Planck Institute for Innovation and Competition ( email )

Marstallplatz 1
Munich, Bayern 80539
Germany

Register to save articles to
your library

Register

Paper statistics

Downloads
142
Abstract Views
751
rank
207,908
PlumX Metrics